onepharm is a Vienna, Austria based innovative dental-pharmaceutical company.
- Phil Stashenko is CEO of the Forsyth Institute, Boston, USA.
- Max Goodson, Director of Clinical Research and a Senior Member of Staff of the Forsyth Institute, Boston, USA; Associate Clinical Professor in the Department of Oral Medicine, Infection and Immunity at the Harvard School of Dental MedicineForsyth Institute, Boston, USA.
- Tom van Dyke, professor at the Boston University, Henry M. Goldman School of Dental Medicine, Executive Director of the International Academy of Periodontolgy, Diplomate of the American Board of Periodontology.
- Jan Lessem, an independent consultant, previously CMO for Orapharma and CombinatoRx.
- Thomas Hoffmann, member of the board and past president of the “Deutsche Gesellschaft für Parodontologie“ and currently president of the “Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde“.
- Victor Brantl is an industry expert with an education in medicine and chemistry and over 25 years of professional experience in drug development at different global pharmaceutical companies.
- Ulrich Jordis, co-founder, is professor for organic chemistry at the Institute of Applied Synthetic Chemistry at the Vienna University of Technology and an expert for medicinal chemistry.
- Andreas Bernkop Schnürch is professor at the Institute of Pharmaceutical Technology at the Leopold Franzens University in Innsbruck and founder of Thiomatrix, a service company for formulation development.
- Udo Elsner, co-founder, is lawyer in Vienna since almost 20 years and an expert in corporate and contract law.
- Eugen Stermetz is a financial and economic expert with several years of consulting experience and was CFO of an Austrian BioTech company for the last 5 years.
